Dimitrios Makrakis
Overview
Explore the profile of Dimitrios Makrakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bakaloudi D, Papaemmanouil A, Vadarlis A, Makrakis D, Germanidis G, Timotheadou E, et al.
Clin Nutr
. 2023 Mar;
42(5):670-686.
PMID: 36944289
Background: The growing incidence of cancer globally, and the importance of nutrition support for these patients, emphasize the need for the development of nutritional clinical practice guidelines and consensus papers...
12.
Diamantopoulos L, Makrakis D, Korentzelos D, Alevizakos M, Wright J, Grivas P, et al.
Urol Oncol
. 2023 Mar;
41(6):296.e17-296.e28.
PMID: 36931981
Introduction: Sarcomatoid urothelial carcinoma (SUC) is a rare and aggressive variant of bladder cancer with limited data guiding prognosis. In this study, we present the first prognostic nomograms in the...
13.
Sharding-Based Proof-of-Stake Blockchain Protocols: Key Components & Probabilistic Security Analysis
Hafid A, Hafid A, Makrakis D
Sensors (Basel)
. 2023 Mar;
23(5).
PMID: 36905022
Blockchain technology has been gaining great interest from a variety of sectors including healthcare, supply chain, and cryptocurrencies. However, Blockchain suffers from a limited ability to scale (i.e., low throughput...
14.
Makrakis D, Rounis K, Tsigkas A, Georgiou A, Galanakis N, Tsakonas G, et al.
PLoS One
. 2023 Feb;
18(2):e0277708.
PMID: 36763597
Obesity and sarcopenia have been reported to affect outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). We analyzed prospective data from 52 patients...
15.
Makrakis D, Wright J, Roudier M, Garcia J, Vakar-Lopez F, Porter M, et al.
Clin Genitourin Cancer
. 2023 Jan;
21(2):265-272.
PMID: 36710146
Introduction: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard for muscle-invasive bladder cancer (MIBC), however, NAC confers only a small survival benefit and new strategies are needed to...
16.
Makrakis D, Bakaloudi D, Talukder R, Lin G, Diamantopoulos L, Jindal T, et al.
Clin Genitourin Cancer
. 2022 Dec;
21(2):286-294.
PMID: 36481176
Objectives: To examine patient and disease characteristics, toxicity, and clinical outcomes for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune checkpoint inhibitor (ICI)-based therapy. Patients And Methods:...
17.
Makrakis D, Holt S, Bernick C, Grivas P, Gore J, Wright J
Alzheimer Dis Assoc Disord
. 2022 Oct;
36(4):307-311.
PMID: 36183417
Introduction: Alzheimer disease (AD) is a common neurodegenerative disease, and immunomodulation offers treatment opportunities. Preclinical data suggest that intravesical Bacillus Calmette-Guerin (BCG) treatment could delay AD development. We investigated this...
18.
Talukder R, Makrakis D, Lin G, Diamantopoulos L, Dawsey S, Gupta S, et al.
Clin Genitourin Cancer
. 2022 Sep;
20(6):558-567.
PMID: 36155169
Background: Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its...
19.
Rallis K, Makrakis D, Ziogas I, Tsoulfas G
World J Clin Oncol
. 2022 Aug;
13(6):448-472.
PMID: 35949435
Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. HCC is an inflammation-associated immunogenic cancer that frequently arises in chronically inflamed livers. Advanced HCC is managed with systemic...
20.
Makrakis D, Talukder R, Lin G, Diamantopoulos L, Dawsey S, Gupta S, et al.
Clin Genitourin Cancer
. 2022 Jul;
20(5):e440-e452.
PMID: 35778337
Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors...